Skip to main content
Home > Week in Review > Clinical Results

Chronological Index of : Clinical Results

 Current Issue
  • AC5 Surgical Hemostatic Device: Clinical trial data

    Arch Therapeutics Inc. (OTCQB:ARTH), Wellesley, Mass. Product: AC5 Surgical Hemostatic Device Business: Hematology Molecular target: NA Description: Device to administer the topical hemostatic agent AC5, a synthetic …

    Published on 8/22/2016
  • Axalimogene filolisbac: Phase II data

    Advaxis Inc. (NASDAQ:ADXS), Princeton, N.J. Product: Axalimogene filolisbac (ADXS11-001) (formerly Lovaxin C, ADXS-HPV) Business: Cancer Molecular target: E7 transforming protein (Human papillomavirus-16) (HpV16gp2) …

    Published on 8/22/2016
  • Buprenorphine: Phase III data

    Indivior plc (LSE:INDV), Richmond, Va. Product: Buprenorphine (RBP-6000) Business: Neurology Molecular target: NA Description: Once-monthly injectable sustained-release formulation of buprenorphine using the Atrigel …

    Published on 8/22/2016
  • Esketamine: Phase II data

    Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Product: Esketamine Business: Neurology Molecular target: NMDA receptor Description: Intranasal NMDA receptor antagonist Indication: Treat major depressive disorder (MDD…

    Published on 8/22/2016
  • IV Baremsis amisulpride: Phase III data

    Acacia Pharma Group plc, Cambridge, U.K. Product: IV Baremsis amisulpride (formerly ACA1421, APD421) Business: Gastrointestinal Molecular target: Dopamine D2 receptor; Dopamine D3 receptor (DRD3) Description: Low-dose …

    Published on 8/22/2016
  • Kevetrin thioureidobutyronitrile: Additional Phase I data

    Cellceutix Corp. (OTCQB:CTIX), Beverly, Mass. Product: Kevetrin thioureidobutyronitrile Business: Cancer Molecular target: Protein kinase B (AKT) (AKT1) (PKB) (PKBA); Leukotriene B4 (LTB4) Description: Small molecule …

    Published on 8/22/2016
  • Keyzilen esketamine hydrochloride: Phase III data

    Auris Medical Holding AG (NASDAQ:EARS), Zug, Switzerland Product: Keyzilen esketamine hydrochloride (AM-101) Business: Other Molecular target: NMDA receptor Description: Intratympanicly injected non-competitive NMDA …

    Published on 8/22/2016
  • LGD-6972: Phase I data

    Ligand Pharmaceuticals Inc. (NASDAQ:LGND), La Jolla, Calif. Product: LGD-6972 Business: Endocrine/Metabolic Molecular target: Glucagon receptor (GCGR) Description: Small molecule glucagon receptor (GCGR) antagonist …

    Published on 8/22/2016
  • Lidocaine vaginal gel: Development discontinued

    Juniper Pharmaceuticals Inc. (NASDAQ:JNP), Boston, Mass. Product: Lidocaine vaginal gel (COL-1077) Business: Neurology Molecular target: Sodium channel Description: Lidocaine bioadhesive 10% vaginal gel Indication: …

    Published on 8/22/2016
  • Luveniq voclosporin: Phase IIb data

    3SBio Inc. (HKSE:1530), Shenyang, China Aurinia Pharmaceuticals Inc. (TSX:AUP; NASDAQ:AUPH), Victoria, B.C. Endo International plc (NASDAQ:ENDP; TSX:ENL), Dublin, Ireland Product: Luveniq voclosporin (LX211) Business: …

    Published on 8/22/2016
  • Medidur fluocinolone acetonide intravitreal implant: Additional Phase III data

    Alimera Sciences Inc. (NASDAQ:ALIM), Alpharetta, Ga. pSivida Corp. (NASDAQ:PSDV; ASX:PVA), Watertown, Mass. Specialised Therapeutics Australia Pty. Ltd., Melbourne, Australia Product: Medidur fluocinolone acetonide …

    Published on 8/22/2016
  • Methylphenidate XR-ODT: Phase I data

    Neos Therapeutics Inc. (NASDAQ:NEOS), Grand Prairie, Texas Product: Methylphenidate XR-ODT (Cotempla XR-ODT) (formerly NT-0102) Business: Neurology Molecular target: NA Description: Extended-release oral disintegrating …

    Published on 8/22/2016
  • NDV-3A: Phase IIa data

    NovaDigm Therapeutics Inc., Grand Forks, N.D. Product: NDV-3A Business: Infectious Molecular target: Agglutinin-like sequence 3 (ALS3) Description: Vaccine containing a recombinant form of the Candida albicans …

    Published on 8/22/2016
  • OTO-104: Phase II data

    Otonomy Inc. (NASDAQ:OTIC), San Diego, Calif. Product: OTO-104 Business: Other Molecular target: NA Description: Sustained-release dexamethasone gel delivered via intratympanic injection Indication: Treat Menieres …

    Published on 8/22/2016
  • Pelareorep: Phase II data

    Oncolytics Biotech Inc. (TSX:ONC; OTCQX:ONCYF), Calgary, Alberta Product: Pelareorep (Reolysin) Business: Cancer Molecular target: NA Description: Formulation of human reovirus type 3, an oncolytic virus Indication: …

    Published on 8/22/2016
  • Px563L: Phase Ia data

    Pfenex Inc. (NYSE-M:PFNX), San Diego, Calif. Product: Px563L Business: Infectious Molecular target: NA Description: Recombinant protective antigen (rPA) anthrax vaccine Indication: Treat and prevent anthrax infection …

    Published on 8/22/2016
  • Secnidazole: Phase III data

    Symbiomix Therapeutics LLC, Newark, N.J. Product: Secnidazole (Solosec) (formerly SYM-1219) Business: Infectious Molecular target: NA Description: Granule formulation of a next-generation, 5-nitroimidazole antibiotic …

    Published on 8/22/2016
  • Single-Dose Sufentanil NanoTab: Additional Phase III data

    AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX), Redwood City, Calif. Product: Single-Dose Sufentanil NanoTab (ARX-04) Business: Neurology Molecular target: Mu opioid receptor (MOR) (OPRM1) Description: Sublingual formulation…

    Published on 8/22/2016
  • Symbicort budesonide/formoterol: Phase III data

    AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Product: Symbicort budesonide/formoterol Business: Inflammation Molecular target: Corticoid receptors; Adrenergic receptor beta 2 (ADRB2) Description: Combination of …

    Published on 8/22/2016
  • Symbicort budesonide/formoterol: Phase IIIb data

    AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Product: Symbicort budesonide/formoterol Business: Pulmonary Molecular target: Corticoid receptors; Adrenergic receptor beta 2 (ADRB2) Description: Combination of …

    Published on 8/22/2016
  • VX-661: Phase III discontinued

    Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), Boston, Mass. Royalty Pharma, New York, N.Y. Product: VX-661 Business: Pulmonary Molecular target: Cystic fibrosis transmembrane conductance regulator (CFTR) Description: Small…

    Published on 8/22/2016
  • Abemaciclib: Interim Phase III data

    Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Product: Abemaciclib (LY2835219) Business: Cancer Molecular target: Cyclin dependent kinase 4 (CDK4); Cyclin dependent kinase 6 (CDK6) Description: Selective dual …

    Published on 8/15/2016
  • ABvac40: Phase I data

    Araclon Biotech S.L., Zaragoza, Spain Product: ABvac40 Business: Neurology Molecular target: Beta amyloid 40 Description: Active immunotherapy targeting the C-terminal fragment of beta amyloid 40 Indication: Treat mild …

    Published on 8/15/2016
  • ATB-346: Phase II data

    Antibe Therapeutics Inc. (TSX-V:ATE; OTCQX:ATBPF), Hamilton, Ontario Product: ATB-346 Business: Autoimmune Molecular target: Cyclooxygenase-1 (COX-1); Cyclooxygenase-2 (COX-2) Description: Hydrogen sulfide-releasing …

    Published on 8/15/2016
  • AUT00206: Phase I data

    Autifony Therapeutics Ltd., London, U.K. Product: AUT00206 Business: Neurology Molecular target: Potassium channel Kv3 Description: Potassium channel Kv3 modulator Indication: Treat schizophrenia Endpoint: Safety and …

    Published on 8/15/2016

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993